Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for Autolus Therapeutics (AUTL) over the last 5 years, with Q3 2025 value amounting to $5.4 million.

  • Autolus Therapeutics' Change in Account Payables rose 186413.04% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year increase of 124317.18%. This contributed to the annual value of $1.6 million for FY2024, which is 41237.72% up from last year.
  • Autolus Therapeutics' Change in Account Payables amounted to $5.4 million in Q3 2025, which was up 186413.04% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Change in Account Payables ranged from a high of $5.4 million in Q3 2025 and a low of -$3.2 million during Q3 2023
  • Over the past 4 years, Autolus Therapeutics' median Change in Account Payables value was $303500.0 (recorded in 2024), while the average stood at $833833.3.
  • Per our database at Business Quant, Autolus Therapeutics' Change in Account Payables crashed by 63027.52% in 2023 and then skyrocketed by 186413.04% in 2025.
  • Over the past 4 years, Autolus Therapeutics' Change in Account Payables (Quarter) stood at $109000.0 in 2022, then plummeted by 630.28% to -$578000.0 in 2023, then soared by 157.27% to $331000.0 in 2024, then skyrocketed by 1537.76% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $1.5 million for Q2 2025, and $1.9 million during Q1 2025.